iPSpine

iPSpine

‌‌

Abstract

The iPSpine consortium was formed to initiate a European-led research effort to identify a future advanced therapeutic strategy that results into a radical new treatment of IDD-induced LBP. With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials. The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs. The iPSpine impact: iPSpine seeks to offer novel technologies and ATMPs for the advanced therapy research and development community. IDD will be the showcase, offering improved quality of life for millions of patients with IDD-induced LBP, through long-lasting reduction of LBP, reduced LBP-related premature retirement, and improved socio-economic contribution.

Consortium

Universiteit Utrecht (Coordinator), Technische Universiteit Eindhoven, Universite De Nantes, Universitair Medisch Centrum Utrecht, NUI Galway, Universitaet Ulm, Universitaet Bern, Institut National De La Sante et de la Recherche Medicale, Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen, AO-Forschungsinstitut Davos, Sheffield Hallam University, Universita Campus Bio Medico Di Roma, Ntrans Technologies BV, Universite De Montpellier, University of Miami, SpineServ GmbH & Co. KG, The University Of Hong Kong, PharmaLex GmbH, Catalyze BV, Stichting Nationaal Reumafonds.